Wilmer Cutler Pickering Hale and Dorr advised Voyager Therapeutics, Inc. on the offering, and Cooley advised the underwriters. Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced an underwritten public offering...
Voyager Therapeutics’ $100 Million Common Stock Offering
Voyager Therapeutics’ Capsid License Agreement and Strategic Collaboration with Novartis
Wilmer Cutler Pickering Hale and Dorr represented Voyager Therapeutics, Inc. in the transaction. Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced a strategic collaboration and capsid license agreement with...
Voyager Therapeutics’ Collaboration Agreement with Neurocrine Biosciences
Wilmer Cutler Pickering Hale and Dorr advised Voyager Therapeutics on the deal. Voyager Therapeutics announced that it entered into a strategic collaboration agreement with Neurocrine Biosciences...
MBX Biosciences’ $115 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised MBX Biosciences on the deal while WilmerHale advised Wellington Management. MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision...
Voyager Therapeutics’ License Option Agreement with Novartis
WilmerHale advised Voyager Therapeutics on the deal. Voyager Therapeutics, a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, announced it entered into...